Pratik S. Upadhyay
Chemist / Consumer Safety Officer, Dedicated Drug Cadre
ORA Division of Pharmaceutical Quality Operations (College Park, GA)
High-impact international investigator specialising in data integrity and cleaning validation — responsible for 88 483s across 13 countries, with 14 warning letters including landmark cases at Intas, Granules India, and Torrent.
Inspection Approach
How Pratik Inspects
Upadhyay is one of FDA's most prolific investigators, with a 483 issuance rate that reflects an uncompromising approach to CGMP compliance. His first-day facility walkthrough is critical to his methodology — at Intas Pharmaceuticals, investigators found a truck loaded with bags of shredded cGMP documents on Day 1, and at Granules India, bird intrusion, dust contamination, and torn records in waste bags were identified during the initial physical assessment.
His signature approach involves deep-dive investigations into OOS results, tracing root cause analyses through multiple layers: interviewing analysts, reviewing chromatographic raw data, and checking whether investigations were extended to other batches and products. At Torrent Pharmaceuticals, he identified that efficacy complaints were not being logged and OOS investigations lacked scientific rigour, leading to a September 2024 warning letter.
Upadhyay is particularly effective at detecting data destruction and falsification. He specifically checks waste disposal areas, waste bags, and uncontrolled paper for evidence of data integrity failures. When issues are found with a single analyst, he demands investigation extension to all work performed by that analyst — a pattern that has turned single findings into facility-wide data integrity crises at multiple Indian manufacturing sites.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
Intas Pharmaceuticals
- Truck loaded with bags of shredded/torn cGMP documents discovered on Day 1 of inspection
- Falsified environmental monitoring plate counts — actual counts under-reported
- Failure to extend batch failure investigations to all affected batches and products
- 36-page Form 483 documenting systemic data integrity failures across the facility
Zydus Lifesciences
- 10 cGMP violations cited across equipment, quality control, and documentation systems
- Equipment qualification and maintenance deficiencies identified during facility walkthrough
Natco Pharma Limited
- OOS investigation deficiencies — root cause conclusions not supported by scientific data
- Laboratory controls gaps identified across multiple analytical testing areas
- Warning letter issued April 2024 following inadequate 483 response
Torrent Pharmaceuticals
- Equipment cleaning failures across shared manufacturing equipment
- Efficacy complaints not being logged in the quality system
- Deficient OOS investigations lacking scientific rationale for root cause conclusions
- Warning letter issued September 2024 with 5 observations
Granules India Limited
- Bird intrusion into manufacturing areas with droppings found in production zones
- Torn cGMP records found in 15+ plastic waste bags — systematic document destruction
- Data recorded on uncontrolled "loose white paper" rather than pre-numbered controlled forms
- Contaminated HVAC ducts with damaged HEPA filters compromising air quality
- Cleaning validation failures with unscientific acceptance criteria for residue limits
- Warning letter issued February 2025 — 26-page 483 with 6 observations
Sandoz Private Limited
- Manufacturing and quality compliance deficiencies identified across multiple areas
Pre-Inspection Preparation
How to Prepare
- 1 Audit waste management areas before any inspection — Upadhyay has found torn cGMP records in waste bags at multiple facilities. Ensure all document destruction follows SOPs with documented evidence.
- 2 Review all OOS investigations for scientific soundness — his citations consistently focus on whether root cause conclusions are supported by data and whether investigations extend to related batches.
- 3 Validate cleaning procedures end-to-end — he rejects MACO-based carryover limits when the underlying cleaning process itself is not validated.
- 4 Ensure facility maintenance is current — physical conditions (walls, HEPA filters, pest control, floor integrity) are inspected during early walkthroughs.
- 5 Verify analyst training and practices through direct observation — he interviews QC analysts and cross-checks documented work against actual practices.
- 6 Extend investigations to all affected analysts and products when any data integrity issue is found — expect a demand for comprehensive scope.
- 7 Confirm Field Alert Report compliance — review your FAR SOP and ensure substantiated complaints trigger timely filings within 3 working days.
- 8 Prepare computer system audit trails for review — he examines chromatographic data integrity, interrupted sequences, and "Project Integrity Failed" messages.
- 9 Ensure environmental monitoring data is accurate — at Intas, he found that plate counts were systematically under-reported.
- 10 Maintain controlled document practices — no data recording on uncontrolled paper. All raw data must be on pre-numbered, controlled forms.
- 11 Review complaint handling processes — he checks whether product quality complaints are properly categorised and Health Hazard Evaluations conducted.
- 12 Document equipment qualification status — every piece of analytical equipment should have current qualification records accessible during inspection.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Pratik S. Upadhyay — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
